PTC THERAPEUTICS, INC.

0001070081 false 0001070081 2026-04-28 2026-04-28 ​ ​ UNITED STATES ​ SECURITIES AND EXCHANGE COMMISSION ​ WASHINGTON, D.C. 20549 ​ FORM 8-K ​ CURRENT REPORT ​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earliest event reported): April 28, 2026 ​ PTC THERAPEUTICS, INC. ​ (Exact Name of Company as Specified in Charter) ​ ​ ​ ​ ​ ​ Delaware ​ ​ ​ 001-35969 ​ ​ ​ 04-3416587 (State or Other Jurisdiction ​ (Commission ​ (IRS Employer of Incorporation) ​ File Number) ​ Identification No.) ​ ​ ​ ​ ​ ​ 500 Warren Corporate Center Drive ​ ​ ​ ​ ​ Warren , NJ ​ ​ 07059 (Address of Principal Executive Offices) ​ ​ (Zip Code) ​ Registrant’s telephone number, including area code: ( 908 ) 222-7000 ​ Not applicable (Former Name or Former Address, if Changed Since Last Report) ​ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ​ ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ​ ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ​ ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ​ Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ ​ ​ ​ Title of each class ​ ​ ​ Trading Symbol(s) ​ ​ ​ Name of each exchange on which registered Common Stock, $0.001 par value per share ​ PTCT ​ Nasdaq Global Select Market ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ ​ ​ Item 7.01 Regulation FD Disclosure. On April 28, 2026, PTC Therapeutics, Inc. (the “Company”) reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam. As previously announced, the Company will also provide a virtual presentation on the results on April 28, 2026 at 4:30 p.m. Eastern time. The presentation will be webcast live on the Events and Presentations page under the Investors section of the Company’s website. The full text of the press release issued in connection with the announcement and the slide presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K (this “Report”), and are incorporated by reference into this Item 7.01. The information in this Item 7.01 (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report. Item 9.01. Financial Statements and Exhibits. (d) Exhibits ​ ​ ​ Exhibit No. ​ ​ ​ Description 99.1 ​ Press Release, dated April 28, 2026 issued by PTC Therapeutics, Inc. 99.2 ​ Corporate Presentation – PIVOT-HD 24-month interim analysis 104 ​ The cover page from this Current Report on Form 8-K, formatted in Inline XBRL ​ ​ ​ ​ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​ ​ ​ PTC Therapeutics, Inc. ​ ​ Date: April 28, 2026 By: /s/ Pierre Gravier ​ Name: Pierre Gravier ​ Title: Chief Financial Officer ​ ​